You are here: Industry Insights > Novartis

News List

Novartis pulls out of antibiotics, cuts 140 staff pharmafile
July 17, 2018
Novartis has announced that it is to terminate its research operations into antibiotics and antivirals in a reorganisation effort that will see 140 staff cut from the company.
Senate claims Novartis misled public on Trump lawyer deal pharmafile
July 17, 2018
A report released by the United States Senate has found that Novartis’ relationship with Donald Trump’s long-time lawyer Michael Cohen “was longer and more detailed than previously disclosed by the company” and that Novartis “explicitly sought to hire Mic
FDA approval for Novartis' melanoma combo pharmatimes
July 12, 2018
The FDA has approved Novartis' Tafinlar(dabrafenib) in combination with Mekinist (trametinib) for the adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma, as detected by an FDA-approved test, and involvement of lymph nodes, following comp
Novartis and Sandoz withdraw medicines from US over packaging concerns pharmaceutical-technology
July 12, 2018
Novartis and its affiliated Sandoz division have voluntarily recalled certain lots of 12 blister packs of medicines from the US market as the packaging did not meet US federal requirements.
EU nod for Sandoz’ Remicade biosimilar Zessly pharmatimes
July 11, 2018
The European Commission has green-lighted Novartis unit Sandoz’ Zessly, a biosimilar version of Johnson & Johnson and Merck's Remicade.
Genmab/Novatis’ Arzerra fails to hit NHL targets pharmatimes
July 11, 2018
Adding Arzerra to treatment with Treanda has failed to significantly extend progression-free survival in patients with indolent B cell non-Hodgkin's lymphoma.
Novartis Announces Recall of Zofran and Entresto Packages americanpharmaceuticalreview
July 11, 2018
Novartis, in cooperation with the U.S. Consumer Product Safety Commission (CPSC) and the Food and Drug Administration (FDA)
Novartis announces intention to spin off Alcon biospectrumasia
July 09, 2018
The planned spinoff would enable Novartis and Alcon to focus fully on their respective growth strategies, said the company in a statement
Novartis dumps Aveo drug as relationship sours fiercebiotech
July 09, 2018
Novartis has walked away from Aveo Pharmaceuticals’ AV-380 three years after paying $15 million (€13 million) upfront for the asset.
Novartis spins off Alcon as CEO focuses drug search pharmafile
July 06, 2018
Novartis has announced a plan to spinoff Alcon – its eye care division – into a separately-traded standalone company.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page